In a move straight out of 2021, BridgeBio Oncology is taking the SPAC route to the public markets in a deal with Helix ...
As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...
ITF, IntraBio and Orchard are among the companies that have won FDA nods in the past year for Duchenne muscular dystrophy, ...
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...
The search for a partner for zerlasiran is ongoing, according to Silence. In the meantime, the biotech will focus its ...
Mission Therapeutics is down to its clinical assets MTX652 and MTX325, which work by disabling a key enzyme that interferes ...
The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...
As it did during the COVID-19 pandemic, mRNA technology offers an efficient way forward in developing products for diseases ...
In the five weeks since Donald Trump returned as U.S. president, the FDA, NIH and CDC have been thrown into disarray, with ...
The back-to-back high-level disruptions in vaccine policy under Robert F. Kennedy Jr. comes as the U.S. records its first ...
The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback